Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults

Inclusion Criteria: * History of HBsAg positive for more than 6 months * HBeAg-positive or HBeAg-negative within 8 weeks * Serum AST or ALT ≥ 80 IU/L * HBe-Ag positive patients: Serum HBV DNA ≥ 1.0 X 10\^5 copies/mL (or 20,000 IU/mL) * HBeAg-negative patients: serum HBV DNA ≥ 1.0 X 10\^4 copies/mL(or 2,000 IU/mL) Exclusion Criteria: * History of antiviral therapy for Chronic hepatitis B within 6 months of study enrollment * Prior treatment of interferon * Presence of viral coinfections (hepatitis C, hepatitis delta, or human immunodeficiency virus) * Other chronic liver disease or decompensated liver disease * platelet\<90,000/mm3 or absolute neutrophil count \< 1,500 mm3 * Pregnant or lactating woman * History of Organ transplantation * Treatment with immunosuppressive/immunomodulatory agents within 6 months prior to study entry